Terns Pharmaceuticals GAAP EPS of -$0.56
- Terns Pharmaceuticals press release (NASDAQ:TERN): Q4 GAAP EPS of -$0.56.
- Q4 Net loss $14.24M.
- As of December 31, 2021, cash, cash equivalents and marketable securities were $166.0 million as compared with $74.9 million as of December 31, 2020.